BioLineRx Ltd.: Form 20-F for the period ended Dec 31, 2017
Filed with the SEC on Mar 6, 2018 and accepted by EDGAR at Mar 6, 2018, 12:06 ET.
Sections
Sections are extracted only from 10-K and 10-Q reports. Read this filing’s documents on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2017-12-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Operating income | 12 months2017-01-01 to 2017-12-31 | −$25.2m | ifrs-full:ProfitLossFromOperatingActivities |
| Net income | 12 months2017-01-01 to 2017-12-31 | −$24.4m | ifrs-full:ProfitLoss |
| Operating cash flow | 12 months2017-01-01 to 2017-12-31 | −$20.5m | ifrs-full:CashFlowsFromUsedInOperatingActivities |
| Capital expenditure | 12 months2017-01-01 to 2017-12-31 | $338.0k | ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities |
| Cash and equivalents | At period end2017-12-31 | $5.1m | ifrs-full:CashAndCashEquivalents |
| Current assets | At period end2017-12-31 | $50.4m | ifrs-full:CurrentAssets |
| Total assets | At period end2017-12-31 | $61.0m | ifrs-full:Assets |
| Current liabilities | At period end2017-12-31 | $6.7m | ifrs-full:CurrentLiabilities |
| Total liabilities | At period end2017-12-31 | $8.1m | ifrs-full:Liabilities |
| Shareholders' equity | At period end2017-12-31 | $52.9m | ifrs-full:Equity |
| Shares outstanding | At period end2017-12-31 | 105,063,437 shares | dei:EntityCommonStockSharesOutstanding |
Source: SEC EDGAR, the filing index for accession 0001178913-18-000765. Last ingested by Listed: Oct 24, 2026, 15:07 ET. Listed shows no prices and gives no investment advice.